Goy, A <br/><br/>
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Mar 2009 
 - 520-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdn656  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Boronic Acids--adverse effects<br/>Bortezomib<br/>Female<br/>Humans<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Pyrazines--adverse effects<br/>Survival Rate<br/>Treatment Outcome